Cargando…

Identification of Cell Type-Specific Differences in Erythropoietin Receptor Signaling in Primary Erythroid and Lung Cancer Cells

Lung cancer, with its most prevalent form non-small-cell lung carcinoma (NSCLC), is one of the leading causes of cancer-related deaths worldwide, and is commonly treated with chemotherapeutic drugs such as cisplatin. Lung cancer patients frequently suffer from chemotherapy-induced anemia, which can...

Descripción completa

Detalles Bibliográficos
Autores principales: Merkle, Ruth, Steiert, Bernhard, Salopiata, Florian, Depner, Sofia, Raue, Andreas, Iwamoto, Nao, Schelker, Max, Hass, Helge, Wäsch, Marvin, Böhm, Martin E., Mücke, Oliver, Lipka, Daniel B., Plass, Christoph, Lehmann, Wolf D., Kreutz, Clemens, Timmer, Jens, Schilling, Marcel, Klingmüller, Ursula
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4975441/
https://www.ncbi.nlm.nih.gov/pubmed/27494133
http://dx.doi.org/10.1371/journal.pcbi.1005049
_version_ 1782446726487998464
author Merkle, Ruth
Steiert, Bernhard
Salopiata, Florian
Depner, Sofia
Raue, Andreas
Iwamoto, Nao
Schelker, Max
Hass, Helge
Wäsch, Marvin
Böhm, Martin E.
Mücke, Oliver
Lipka, Daniel B.
Plass, Christoph
Lehmann, Wolf D.
Kreutz, Clemens
Timmer, Jens
Schilling, Marcel
Klingmüller, Ursula
author_facet Merkle, Ruth
Steiert, Bernhard
Salopiata, Florian
Depner, Sofia
Raue, Andreas
Iwamoto, Nao
Schelker, Max
Hass, Helge
Wäsch, Marvin
Böhm, Martin E.
Mücke, Oliver
Lipka, Daniel B.
Plass, Christoph
Lehmann, Wolf D.
Kreutz, Clemens
Timmer, Jens
Schilling, Marcel
Klingmüller, Ursula
author_sort Merkle, Ruth
collection PubMed
description Lung cancer, with its most prevalent form non-small-cell lung carcinoma (NSCLC), is one of the leading causes of cancer-related deaths worldwide, and is commonly treated with chemotherapeutic drugs such as cisplatin. Lung cancer patients frequently suffer from chemotherapy-induced anemia, which can be treated with erythropoietin (EPO). However, studies have indicated that EPO not only promotes erythropoiesis in hematopoietic cells, but may also enhance survival of NSCLC cells. Here, we verified that the NSCLC cell line H838 expresses functional erythropoietin receptors (EPOR) and that treatment with EPO reduces cisplatin-induced apoptosis. To pinpoint differences in EPO-induced survival signaling in erythroid progenitor cells (CFU-E, colony forming unit-erythroid) and H838 cells, we combined mathematical modeling with a method for feature selection, the L(1) regularization. Utilizing an example model and simulated data, we demonstrated that this approach enables the accurate identification and quantification of cell type-specific parameters. We applied our strategy to quantitative time-resolved data of EPO-induced JAK/STAT signaling generated by quantitative immunoblotting, mass spectrometry and quantitative real-time PCR (qRT-PCR) in CFU-E and H838 cells as well as H838 cells overexpressing human EPOR (H838-HA-hEPOR). The established parsimonious mathematical model was able to simultaneously describe the data sets of CFU-E, H838 and H838-HA-hEPOR cells. Seven cell type-specific parameters were identified that included for example parameters for nuclear translocation of STAT5 and target gene induction. Cell type-specific differences in target gene induction were experimentally validated by qRT-PCR experiments. The systematic identification of pathway differences and sensitivities of EPOR signaling in CFU-E and H838 cells revealed potential targets for intervention to selectively inhibit EPO-induced signaling in the tumor cells but leave the responses in erythroid progenitor cells unaffected. Thus, the proposed modeling strategy can be employed as a general procedure to identify cell type-specific parameters and to recommend treatment strategies for the selective targeting of specific cell types.
format Online
Article
Text
id pubmed-4975441
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-49754412016-08-25 Identification of Cell Type-Specific Differences in Erythropoietin Receptor Signaling in Primary Erythroid and Lung Cancer Cells Merkle, Ruth Steiert, Bernhard Salopiata, Florian Depner, Sofia Raue, Andreas Iwamoto, Nao Schelker, Max Hass, Helge Wäsch, Marvin Böhm, Martin E. Mücke, Oliver Lipka, Daniel B. Plass, Christoph Lehmann, Wolf D. Kreutz, Clemens Timmer, Jens Schilling, Marcel Klingmüller, Ursula PLoS Comput Biol Research Article Lung cancer, with its most prevalent form non-small-cell lung carcinoma (NSCLC), is one of the leading causes of cancer-related deaths worldwide, and is commonly treated with chemotherapeutic drugs such as cisplatin. Lung cancer patients frequently suffer from chemotherapy-induced anemia, which can be treated with erythropoietin (EPO). However, studies have indicated that EPO not only promotes erythropoiesis in hematopoietic cells, but may also enhance survival of NSCLC cells. Here, we verified that the NSCLC cell line H838 expresses functional erythropoietin receptors (EPOR) and that treatment with EPO reduces cisplatin-induced apoptosis. To pinpoint differences in EPO-induced survival signaling in erythroid progenitor cells (CFU-E, colony forming unit-erythroid) and H838 cells, we combined mathematical modeling with a method for feature selection, the L(1) regularization. Utilizing an example model and simulated data, we demonstrated that this approach enables the accurate identification and quantification of cell type-specific parameters. We applied our strategy to quantitative time-resolved data of EPO-induced JAK/STAT signaling generated by quantitative immunoblotting, mass spectrometry and quantitative real-time PCR (qRT-PCR) in CFU-E and H838 cells as well as H838 cells overexpressing human EPOR (H838-HA-hEPOR). The established parsimonious mathematical model was able to simultaneously describe the data sets of CFU-E, H838 and H838-HA-hEPOR cells. Seven cell type-specific parameters were identified that included for example parameters for nuclear translocation of STAT5 and target gene induction. Cell type-specific differences in target gene induction were experimentally validated by qRT-PCR experiments. The systematic identification of pathway differences and sensitivities of EPOR signaling in CFU-E and H838 cells revealed potential targets for intervention to selectively inhibit EPO-induced signaling in the tumor cells but leave the responses in erythroid progenitor cells unaffected. Thus, the proposed modeling strategy can be employed as a general procedure to identify cell type-specific parameters and to recommend treatment strategies for the selective targeting of specific cell types. Public Library of Science 2016-08-05 /pmc/articles/PMC4975441/ /pubmed/27494133 http://dx.doi.org/10.1371/journal.pcbi.1005049 Text en © 2016 Merkle et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Merkle, Ruth
Steiert, Bernhard
Salopiata, Florian
Depner, Sofia
Raue, Andreas
Iwamoto, Nao
Schelker, Max
Hass, Helge
Wäsch, Marvin
Böhm, Martin E.
Mücke, Oliver
Lipka, Daniel B.
Plass, Christoph
Lehmann, Wolf D.
Kreutz, Clemens
Timmer, Jens
Schilling, Marcel
Klingmüller, Ursula
Identification of Cell Type-Specific Differences in Erythropoietin Receptor Signaling in Primary Erythroid and Lung Cancer Cells
title Identification of Cell Type-Specific Differences in Erythropoietin Receptor Signaling in Primary Erythroid and Lung Cancer Cells
title_full Identification of Cell Type-Specific Differences in Erythropoietin Receptor Signaling in Primary Erythroid and Lung Cancer Cells
title_fullStr Identification of Cell Type-Specific Differences in Erythropoietin Receptor Signaling in Primary Erythroid and Lung Cancer Cells
title_full_unstemmed Identification of Cell Type-Specific Differences in Erythropoietin Receptor Signaling in Primary Erythroid and Lung Cancer Cells
title_short Identification of Cell Type-Specific Differences in Erythropoietin Receptor Signaling in Primary Erythroid and Lung Cancer Cells
title_sort identification of cell type-specific differences in erythropoietin receptor signaling in primary erythroid and lung cancer cells
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4975441/
https://www.ncbi.nlm.nih.gov/pubmed/27494133
http://dx.doi.org/10.1371/journal.pcbi.1005049
work_keys_str_mv AT merkleruth identificationofcelltypespecificdifferencesinerythropoietinreceptorsignalinginprimaryerythroidandlungcancercells
AT steiertbernhard identificationofcelltypespecificdifferencesinerythropoietinreceptorsignalinginprimaryerythroidandlungcancercells
AT salopiataflorian identificationofcelltypespecificdifferencesinerythropoietinreceptorsignalinginprimaryerythroidandlungcancercells
AT depnersofia identificationofcelltypespecificdifferencesinerythropoietinreceptorsignalinginprimaryerythroidandlungcancercells
AT raueandreas identificationofcelltypespecificdifferencesinerythropoietinreceptorsignalinginprimaryerythroidandlungcancercells
AT iwamotonao identificationofcelltypespecificdifferencesinerythropoietinreceptorsignalinginprimaryerythroidandlungcancercells
AT schelkermax identificationofcelltypespecificdifferencesinerythropoietinreceptorsignalinginprimaryerythroidandlungcancercells
AT hasshelge identificationofcelltypespecificdifferencesinerythropoietinreceptorsignalinginprimaryerythroidandlungcancercells
AT waschmarvin identificationofcelltypespecificdifferencesinerythropoietinreceptorsignalinginprimaryerythroidandlungcancercells
AT bohmmartine identificationofcelltypespecificdifferencesinerythropoietinreceptorsignalinginprimaryerythroidandlungcancercells
AT muckeoliver identificationofcelltypespecificdifferencesinerythropoietinreceptorsignalinginprimaryerythroidandlungcancercells
AT lipkadanielb identificationofcelltypespecificdifferencesinerythropoietinreceptorsignalinginprimaryerythroidandlungcancercells
AT plasschristoph identificationofcelltypespecificdifferencesinerythropoietinreceptorsignalinginprimaryerythroidandlungcancercells
AT lehmannwolfd identificationofcelltypespecificdifferencesinerythropoietinreceptorsignalinginprimaryerythroidandlungcancercells
AT kreutzclemens identificationofcelltypespecificdifferencesinerythropoietinreceptorsignalinginprimaryerythroidandlungcancercells
AT timmerjens identificationofcelltypespecificdifferencesinerythropoietinreceptorsignalinginprimaryerythroidandlungcancercells
AT schillingmarcel identificationofcelltypespecificdifferencesinerythropoietinreceptorsignalinginprimaryerythroidandlungcancercells
AT klingmullerursula identificationofcelltypespecificdifferencesinerythropoietinreceptorsignalinginprimaryerythroidandlungcancercells